Abstract:Selective Mcl-1 inhibitors may overcome the drug resistance caused by current anti-apoptotic Bcl-2 protein inhibitors in tumors with Mcl-1 overexpression. Based on previously discovered compounds with a 3-phenylthiophene-2-sulfonamide core moiety, in this work, we have obtained new compounds with improved binding affinity and/or selectivity under the guidance of structure-based design. The most potent compounds achieved sub-micromolar binding affinities to Mcl-1 (Ki ∼ 0.4 μM) and good cytotoxicity (IC50 < 10 μM) on several tumor cells. 15N-heteronuclear single-quantum coherence NMR spectra suggested that these compounds bound to the BH3-binding groove on Mcl-1. Several cellular assays revealed that FWJ-D4 as well as its precursor FWJ-D5 effectively induced caspase-dependent apoptosis, and their target engagement at Mcl-1 was confirmed by co-immunoprecipitation experiments. Treatment with FWJ-D5 at 50 mg/kg every 2 days on an RS4;11 xenograft mouse model for 22 days led to 75% reduction in tumor volume without body weight loss.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00690?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00690</a>.Information of the predicted hydration sites in the Mcl-1 binding pocket, flow cytometric analysis of three selected compounds, and HPLC traces for the reported compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00690/suppl_file/jm1c00690_si_001.pdf">PDF</a>)Molecular formula strings of all reported compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00690/suppl_file/jm1c00690_si_002.csv">CSV</a>)Structural files of the predicted binding modes of YCW-E10 and FWJ-D4 with Mcl-1 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00690/suppl_file/jm1c00690_si_003.zip">ZIP</a>)Statement on the ethnicity of all animal experiments performed in this work (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00690/suppl_file/jm1c00690_si_004.pdf">PDF</a>)This article has not yet been cited by other publications.

Supplementary Methods and Supplementary Figures 1 Through 9 from A Novel Small-Molecule Inhibitor of Mcl-1 Blocks Pancreatic Cancer Growth <i>in Vitro</i> and <i>in Vivo</i>

Supplementary Figure 3 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Methods, Figures 1-3 from Synergistic Antitumor Activity of Gemcitabine and ABT-737 in Vitro and in Vivo Through Disrupting the Interaction of USP9X and Mcl-1

Supplementary Figure 2 from Small-Molecule Inhibitor BMS-777607 Induces Breast Cancer Cell Polyploidy with Increased Resistance to Cytotoxic Chemotherapy Agents

Supplementary Methods, Figures 1-15 from SM-164: A Novel, Bivalent Smac Mimetic That Induces Apoptosis and Tumor Regression by Concurrent Removal of the Blockade of Ciap-1/2 and XIAP

Supplementary Figure 1 from Small-Molecule Inhibitor BMS-777607 Induces Breast Cancer Cell Polyploidy with Increased Resistance to Cytotoxic Chemotherapy Agents

The Anti-Tumor Effect of a Novel Agent MCL/ACT001 in Pancreatic Ductal Adenocarcinoma

Supplementary Figure 1 from Mitoxantrone Targets Human Ubiquitin-Specific Peptidase 11 (USP11) and is a Potent Inhibitor of Pancreatic Cancer Cell Survival

Supplementary Figures 1-3 from OSI-930: A Novel Selective Inhibitor of Kit and Kinase Insert Domain Receptor Tyrosine Kinases with Antitumor Activity in Mouse Xenograft Models

The Antitumor Effect of the Novel Agent MCL/ACT001 in Pancreatic Ductal Adenocarcinoma

Supplementary Figures 1-9 from Combined Treatment of Pancreatic Cancer with Mithramycin A and Tolfenamic Acid Promotes Sp1 Degradation and Synergistic Antitumor Activity

Supplementary Methods from Novel Pyrrolo[3,2-d]pyrimidine Compounds Target Mitochondrial and Cytosolic One-carbon Metabolism with Broad-spectrum Antitumor Efficacy

Supplemental Methods from Multikinase Inhibitor CT-707 Targets Liver Cancer by Interrupting the Hypoxia-Activated IGF-1R–YAP Axis

Structure-Based Optimization of 3-Phenyl- N -(2-(3-phenylureido)ethyl)thiophene-2-sulfonamide Derivatives as Selective Mcl-1 Inhibitors

Supplementary Figure S4 from the Novel SMAC Mimetic Birinapant Exhibits Potent Activity Against Human Melanoma Cells

Supplementary Figure S5 from the Novel SMAC Mimetic Birinapant Exhibits Potent Activity Against Human Melanoma Cells

Supplementary Figure 9 from Personalized Chemotherapy Profiling Using Cancer Cell Lines from Selectable Mice

Supplementary Table 1 from A Small-Molecule Inhibitor of Glucose Transporter 1 Downregulates Glycolysis, Induces Cell-Cycle Arrest, and Inhibits Cancer Cell Growth <i>in Vitro</i> and <i>in Vivo</i>

Supplementary Figures 1-6 from Combining Betulinic Acid and Mithramycin A Effectively Suppresses Pancreatic Cancer by Inhibiting Proliferation, Invasion, and Angiogenesis

Supplementary Methods from AZ1366: an Inhibitor of Tankyrase and the Canonical Wnt Pathway That Limits the Persistence of Non–Small Cell Lung Cancer Cells Following EGFR Inhibition

Structure-Based Virtual Screening, Biological Evaluation And Biophysical Study Of Novel Mcl-1 Inhibitors

Supplementary Methods and Supplementary Figures 1 Through 9 from A Novel Small-Molecule Inhibitor of Mcl-1 Blocks Pancreatic Cancer Growth &lt;i&gt;in Vitro&lt;/i&gt; and &lt;i&gt;in Vivo&lt;/i&gt;